Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced it will present new findings on its lead compound buntanetap at the 2025 Annual Meeting of the Parkinson Study Group, held December 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results, which showed that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap. The drug also reduces tau biomarkers linked to disease progression.
In addition to the biomarker data, Annovis will debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications. The analysis underscores that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the company’s strategic path forward. This presentation is significant because it provides a clearer understanding of which patient subgroups may benefit most from buntanetap, potentially guiding future clinical development and personalized treatment approaches.
The Parkinson Study Group meeting is a key venue for presenting research on Parkinson’s disease, and Annovis’s inclusion highlights the growing interest in buntanetap as a potential therapy. The company is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The press release was distributed by InvestorWire, a specialized communications platform. For the full press release, visit https://ibn.fm/xiBPL. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
These data are important because they suggest that buntanetap may address a previously unrecognized subgroup of Parkinson’s patients—those with amyloid co-pathology—who have worse cognitive outcomes but may respond well to treatment. The reduction in tau biomarkers also indicates a potential disease-modifying effect. If confirmed in further studies, buntanetap could become a significant therapeutic option for Parkinson’s disease, which currently has limited treatments for cognitive decline.
